Gene · 1633
Papers2,658
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,658
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pancreatic cancer, stroma, and exosomes. | J Physiol Biochem | 2023 | 35644825 | PubTator, text mining | PubMed |
| Experience of surgical treatment in a granular cell tumor in the ascending colon: a case report. | Ann Coloproctol | 2023 | 34228911 | PubTator, text mining | PubMed |
| Gemcitabine in combination with epibrassinolide enhanced the apoptotic response in an ER stress-dependent manner and reduced the epithelial-mesenchymal transition in pancreatic cancer cells. | Turk J Biol | 2022 | 37529796 | PubTator, text mining | PubMed |
| Therapeutic Applications of Curcumin and Derivatives in Colorectal Cancer. | Onco Ther | 2022 | 37324055 | PubTator, text mining | PubMed |
| Recent progress in DNA methyltransferase inhibitors as anticancer agents. | Front Pharmacol | 2022 | 37077808 | PubTator, text mining | PubMed |
| The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer. | Technol Cancer Res Treat | 2022 | 36976899 | PubTator, text mining | PubMed |
| A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its Ecosystem. | Adv Genet (Hoboken) | 2022 | 36911295 | PubTator, text mining | PubMed |
| Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review. | Cureus | 2022 | 36726936 | PubTator, text mining | PubMed |
| The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. | Front Immunol | 2022 | 36700226 | PubTator, text mining | PubMed |
| The role of metabolic reprogramming in pancreatic cancer chemoresistance. | Front Pharmacol | 2022 | 36699061 | PubTator, text mining | PubMed |
| Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus. | Front Endocrinol (Lausanne) | 2022 | 36686441 | PubTator, text mining | PubMed |
| New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme. | Explor Target Antitumor Ther | 2022 | 36654821 | PubTator, text mining | PubMed |
| The Effect of Oxidative Phosphorylation on Cancer Drug Resistance. | Cancers (Basel) | 2022 | 36612059 | PubTator, text mining | PubMed |
| Low Expression of Phosphodiesterase 2 (PDE2A) Promotes the Progression by Regulating Mitochondrial Morphology and ATP Content and Predicts Poor Prognosis in Hepatocellular Carcinoma. | Cells | 2022 | 36611861 | PubTator, text mining | PubMed |
| A Dual Cluster-Head Energy-Efficient Routing Algorithm Based on Canopy Optimization and K-Means for WSN. | Sensors (Basel) | 2022 | 36560099 | PubTator, text mining | PubMed |
| Antiviral Potential of Small Molecules Cordycepin, Thymoquinone, and N6, N6-Dimethyladenosine Targeting SARS-CoV-2 Entry Protein ADAM17. | Molecules | 2022 | 36558177 | PubTator, text mining | PubMed |
| Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients. | Brain Sci | 2022 | 36552055 | PubTator, text mining | PubMed |
| Non-coding RNA-related antitumor mechanisms of marine-derived agents. | Front Pharmacol | 2022 | 36532760 | PubTator, text mining | PubMed |
| Comparative analysis of the DNA methylation landscape in CD4, CD8, and B memory lineages. | Clin Epigenetics | 2022 | 36522672 | PubTator, text mining | PubMed |
| Emerging current trends and research focus related to pancreatic cancer metabolism: A bibliometric and visualized analysis. | Front Oncol | 2022 | 36505775 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1633/papers?page=12